INFLUENCE OF CYP3A5 GENOTYPE ON THE PHARMACOKINETIC PROFILE OF TACROLIMUS IN PAEDIATRIC TRANSPLANT PATIENTS

被引：0
|
作者：
McLean, K.
Fung, A.
Gijsen, V.
Nalli, N.
Safi, M.
Daljevic, T.
Ogaki, C.
Mital, S.
机构：
来源：
CANADIAN JOURNAL OF CARDIOLOGY | 2012年 / 28卷 / 05期
关键词：
D O I：
10.1016/j.cjca.2012.07.471
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [31] CYP3A5 polymorphism and tacrolimus pharmacokinetic/pharmacodynamic interactions in young kidney transplant recipients.
    Ghio, L.
    Ferraresso, M.
    Tirelli, S.
    Grillo, P.
    Belingheri, M.
    Martina, V.
    Torresani, E.
    Berardinelli, L.
    Edefonti, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 577 - 577
  • [32] Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes
    Hu, Can
    Yin, Wen-jun
    Li, Dai-yang
    Ding, Jun-jie
    Zhou, Ling-yun
    Wan, Jiang-lin
    Ma, Rong-rong
    Liu, Kun
    Zhou, Ge
    Zuo, Xiao-cong
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (11) : 1437 - 1447
  • [33] Tacrolimus dose could be individualized according to CYP3A5 genotype
    Nature Clinical Practice Nephrology, 2007, 3 (7): : 358 - 358
  • [34] CYP3A5 Genotype Had no Impact on Intrapatient Variability of Tacrolimus Clearance in Renal Transplant Recipients
    Spierings, N.
    Holt, D. W.
    MacPhee, Iain A. M.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (03) : 328 - 331
  • [35] CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients
    Yanik, Megan V.
    Seifert, Michael E.
    Locke, Jayme E.
    Hauptfeld-Dolejsek, Vera
    Crowley, Michael R.
    Cutter, Gary R.
    Mannon, Roslyn B.
    Feig, Daniel I.
    Limdi, Nita A.
    PEDIATRIC TRANSPLANTATION, 2019, 23 (05)
  • [36] THE INFLUENCE OF CYP3A4 AND CYP3A5 GENOTYPE AND PHENOTYPE ON THE PHARMACOKINETICS OF TACROLIMUS IN HEALTHY CHINESE.
    Jiao, Z.
    Shi, X.
    Geng, F.
    Cui, X.
    Qiu, X.
    Zhong, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S52 - S52
  • [37] CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus Clearance
    Pashaee, Nilufar
    Bouamar, Rachida
    Hesselink, Dennis A.
    Roodnat, Joke I.
    van Schaik, Ron H. N.
    Weimar, Willem
    van Gelder, Teun
    THERAPEUTIC DRUG MONITORING, 2011, 33 (03) : 369 - 371
  • [38] THE ASSOCIATION OF BODYWEIGHT AND CYP3A5 GENOTYPE WITH TACROLIMUS TROUGH LEVEL IN CHINESE RENAL TRANSPLANT RECIPIENTS
    Tang, Jang-Tao
    Shi, Yun-Ying
    Li, Yi
    Yan, Lin
    Wang, Ting-Li
    Bai, Yang-Juan
    Zou, Yuan-Gao
    Tao, Ye
    Wang, Lan-Lan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 415 - 416
  • [39] Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients
    Largeau, Berenger
    Barin-Le Guellec, Chantal
    Longuet, Helene
    Lesne, Philippe
    Bouvarel, Antoine
    Preteseille, Laura
    Marquet, Pierre
    Halimi, Jean-Michel
    Buchler, Matthias
    Gatault, Philippe
    Noble, Johan
    PROGRESS IN TRANSPLANTATION, 2019, 29 (04) : 300 - 308
  • [40] Influence of CYP3A5 polymorphism on pharmacokinetic interaction of fluconazole and tacrolimus, and effect of fluconazole on everolimus pharmacokinetics in heart transplant recipient
    Terada, Yuka
    Wada, Kyoichi
    Matsuda, Sachi
    Kuwahara, Takeshi
    Kawabata, Atsufumi
    Takada, Mitsutaka
    Hisamatsu, Eriko
    Sunami, Haruki
    Nakajima, Seiko
    Sato, Takuma
    Seguchi, Osamu
    Yanase, Masanobu
    Fukushima, Norihide
    Nakatani, Takeshi
    TRANSPLANTATION, 2016, 100 (07) : S825 - S826
12345